Pharmacologic risk factor management in peripheral arterial disease: A vade mecum for vascular surgeons

Journal of Vascular Surgery

Volumn 47, Issue 5, 2008, Pages 1108-1115

  Rehring, Thomas F ^a   Stolcpart, Ryan S ^a   Hollis Jr , H Whitton ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MEVINOLIN; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINIC AGENT; PLACEBO; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; VARENICLINE;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTERY DISEASE; BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; MOUTH DISEASE; MYALGIA; MYOPATHY; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOSE IRRITATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; STROKE; SURGEON; THERAPY EFFECT; THROAT IRRITATION; TOBACCO DEPENDENCE; ULCER; UNSPECIFIED SIDE EFFECT; URTICARIA; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIFE STYLE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SMOKING; SMOKING CESSATION; VASCULAR SURGICAL PROCEDURES;

EID: 43049102998     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.12.033     Document Type: Review

References (68)

1. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47 (2006) 1239-12
2. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
5. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
6. Smith Jr. S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372
7. Bianchi C., Montalvo V., Ou H.W., Bishop V., and Abou-Zamzam Jr. A.M. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 21 (2007) 163-166
8. Leon Jr. L.R., Labropoulos N., Lebda P., and Kalman P.G. The vascular surgeon's role in risk factor modification: results of a survey. Perspect Vasc Surg Endovasc Ther 17 (2005) 145-153
9. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., and Fowkes F.G. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 suppl S (2007) S5-S67
10. McDermott M.M., Hahn E.A., Greenland P., Cella D., Ockene J.K., Brogan D., et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med 17 (2002) 895-904
11. Kalman P.G., Irvine J., and Ritvo P. How do vascular surgeons perceive atherosclerotic risk factor management?. Ann Vasc Surg 14 (2000) 652-658
12. Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114 (2006) 82-96
13. Purnell J.Q., Kahn S.E., Albers J.J., Nevin D.N., Brunzell J.D., and Schwartz R.S. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85 (2000) 977-982
14. Jenkins D.J., Kendall C.W., Marchie A., Faulkner D.A., Wong J.M., de Souza R., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290 (2003) 502-510
15. Stefanick M.L., Mackey S., Sheehan M., Ellsworth N., Haskell W.L., and Wood P.D. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 339 (1998) 12-20
16. Sacks F.M., and Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 113 suppl 9B (2002) 13S-24S
17. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
18. Selvin E., and Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110 (2004) 738-743
19. Critchley J., and Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database (2004) CD003041
20. Wilson K., Gibson N., Willan A., and Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 160 (2000) 939-944
21. Godtfredsen N.S., Holst C., Prescott E., Vestbo J., and Osler M. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol 156 (2002) 994-1001
22. Bjartveit K., and Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tobacco Control 14 (2005) 315-320
23. Anderson J.E., Jorenby D.E., Scott W.J., and Fiore M.C. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 121 (2002) 932-941
24. Fiore M.C. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 45 (2000) 1200-1262
25. Lancaster T., and Stead L.F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev (2005) CD001292
26. Stead L.F., and Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev (2005) CD001007
27. Stead L.F., Perera R., and Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 3 (2006) CD002850
28. Greenland S., Satterfield M.H., and Lanes S.F. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf 18 (1998) 297-308
29. Joseph A.M., Norman S.M., Ferry L.H., Prochazka A.V., Westman E.C., Steele B.G., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 (1996) 1792-1798
30. Ford C.L., and Zlabek J.A. Nicotine replacement therapy and cardiovascular disease. Mayo Clinic Proc 80 (2005) 652-656
31. Silagy C., Lancaster T., Stead L., Mant D., and Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2004) CD000146
32. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
33. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev (2007) CD000031
34. Simon J.A., Duncan C., Carmody T.P., and Hudes E.S. Bupropion for smoking cessation: a randomized trial. Arch Intern Med 164 (2004) 1797-1803
35. Swan G.E., McAfee T., Curry S.J., Jack L.M., Javitz H., Dacey S., et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 163 (2003) 2337-2344
36. Cahill K., Stead L.F., and Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2007) CD006103
37. Gonzales D., Rennard S.I., Nides M., Oncken C., Azoulay S., Billing C.B., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
38. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
39. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 166 (2006) 1561-1568
40. Tonstad S., Tonnesen P., Hajek P., Williams K.E., Billing C.B., and Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296 (2006) 64-71
41. Wallis E.J., Ramsay L.E., Ul Haq I., Ghahramani P., Jackson P.R., Rowland-Yeo K., et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 320 (2000) 671-676
42. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
43. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
44. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
45. Tonkin A.M., Colquhoun D., Emberson J., Hague W., Keech A., Lane G., et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 356 (2000) 1871-1875
46. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
47. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., and Furberg C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97 (1998) 946-952
48. Liao J.K. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96 (2005) 24F-33F
49. Feringa H.H., Karagiannis S.E., van Waning V.H., Boersma E., Schouten O., Bax J.J., et al. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 45 (2007) 936-943
50. McDermott M.M., Guralnik J.M., Greenland P., Pearce W.H., Criqui M.H., Liu K., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107 (2003) 757-761
51. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
52. Mondillo S., Ballo P., Barbati R., Guerrini F., Ammaturo T., Agricola E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003) 359-364
53. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
54. Bradford R.H., Shear C.L., Chremos A.N., Dujovne C.A., Franklin F.A., Grillo R.B., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 74 (1994) 667-673
55. Pedersen T.R., Berg K., Cook T.J., Faergeman O., Haghfelt T., Kjekshus J., et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156 (1996) 2085-2092
56. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
57. Campbell C.L., Smyth S., Montalescot G., and Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297 (2007) 2018-2024
58. Kelly J.P., Kaufman D.W., Jurgelon J.M., Sheehan J., Koff R.S., and Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
59. Karha J., Rajagopal V., Kottke-Marchant K., and Bhatt D.L. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 151 (2006) 976 e977-11
60. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
61. Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007) 1982-1988
62. Hebert P.R., Moser M., Mayer J., Glynn R.J., and Hennekens C.H. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 153 (1993) 578-581
63. Hennekens C.H., Albert C.M., Godfried S.L., Gaziano J.M., and Buring J.E. Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 335 (1996) 1660-1667
64. Teo K.K., Yusuf S., and Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270 (1993) 1589-1595
65. Radack K., and Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 151 (1991) 1769-1776
66. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
67. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
68. Grundy S.M., Balady G.J., Criqui M.H., Fletcher G., Greenland P., Hiratzka L.F., et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 95 (1997) 1683-1685